Therapeutic Antibodies and Monoclonal Antibody Technology

Monoclonal antibodies are antibodies of a single defined specificity produced in unlimited quantity, made possible by hybridoma technology and later by recombinant engineering. They have become both indispensable laboratory reagents and one of the most important classes of modern biologic therapeutics, exploiting natural antibody recognition and effector functions for designed purposes.

Definition

A monoclonal antibody is an antibody of a single, defined specificity produced by a clonal cell line; monoclonal antibody technology comprises the methods, beginning with hybridoma fusion and extending to recombinant engineering, used to generate, humanise, and tailor such antibodies.

Scope

The topic covers the principle of monoclonal antibodies, the hybridoma method, the engineering steps that reduced immunogenicity (chimeric, humanised, and fully human antibodies), recombinant display technologies, and how Fc properties are tuned for effector or non-effector roles. It treats therapeutic antibodies as technology and mechanism for reference and gives no dosing or treatment advice.

Core questions

• How does the hybridoma method yield a single defined antibody specificity?
• Why and how are mouse-derived antibodies humanised for therapeutic use?
• How do display technologies generate fully human antibodies?
• How is the Fc region engineered to enhance or silence effector function?

Key concepts

• Hybridoma technology
• Clonal (single-specificity) antibody
• Chimeric and humanised antibodies
• Fully human antibodies
• Complementarity-determining region grafting
• Phage and recombinant display
• Fc engineering
• Immunogenicity

Mechanisms

Köhler and Milstein's hybridoma method fuses an antibody-producing B cell with an immortal myeloma cell, creating a hybrid that both survives indefinitely and secretes a single antibody specificity, which can be selected and grown as a clone. Because early monoclonals were murine and provoked anti-mouse responses in patients, engineering progressively replaced mouse sequence with human sequence: chimeric antibodies keep mouse variable regions on human constant regions, humanised antibodies graft only the mouse complementarity-determining regions onto a human framework, and fully human antibodies are obtained from display libraries or transgenic systems. The Fc region can be engineered to strengthen effector functions such as antibody-dependent cytotoxicity and complement activation, or to silence them when only neutralisation or receptor blockade is wanted, and Fc properties also influence half-life.

Clinical relevance

Monoclonal antibodies are used across oncology, autoimmune and inflammatory disease, infection, and diagnostics, and the choice of isotype and Fc engineering reflects the desired mechanism. The topic describes how these agents are built and how their mechanisms relate to antibody biology; it is not a source of prescribing information or individualized treatment guidance.

History

The 1975 hybridoma method of Köhler and Milstein, recognised with a Nobel Prize, made defined monoclonal antibodies routine. The immunogenicity of murine antibodies then drove the development of chimeric and humanised antibodies in the 1980s, complementarity-determining region grafting and display technologies enabling human antibodies in the following years, and Fc engineering more recently, together producing the contemporary landscape of antibody therapeutics.

Key figures

• Georges Köhler
• César Milstein
• Greg Winter
• Janice Reichert

Seminal works

• kohler-milstein-1975
• jones-1986

Frequently asked questions

What makes an antibody monoclonal?

It is produced by a single clonal cell line and therefore has one defined specificity and structure, in contrast to the polyclonal mixture of antibodies present in serum.

Why are therapeutic antibodies humanised?

Antibodies originally raised in mice can provoke an immune response against the foreign mouse sequence; humanisation replaces most or all of that sequence with human sequence, typically by grafting only the antigen-binding loops onto a human framework, to reduce immunogenicity.